logo

Getting ready to treat human patients with nanobody-targeted photodynamic therapy

Sector: Commercial • Location: Netherlands

Source: EU Funding & Tenders Portal

Project
Ended

Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term protection through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach which can do both, through the local light activation of photosensi

Project Information FAQ

Project Information

4 Q
The project “Getting ready to treat human patients with nanobody-targeted photodynamic therapy” is an infrastructure initiative in the Commercial sector, located in Netherlands. Taiyo aggregates data on it from EU Funding & Tenders Portal.

Want to explore the full details? View the full report

Participants

Sponsoring Agency

Obfuscated Data

Company

Obfuscated Data

Status

Original status

ended

Taiyo status

Obfuscated Data

Taiyo last update

00-00-0000

Available timestamps

00-00-0000

Available timestamp type

Obfuscated Data

Contact

Contact name

Obfuscated Data

Phone

0000000000

Email

ObfuscatedData@email.com

Address

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Description

Description

Unfortunately, current cancer therapies often fail to cure patients, or are associated with severe side effects. Ideally, a therapy should locally eradicate cancer cells without damaging healthy tissue and should induce long term protection through activation of the immune system. Photodynamic therapy (PDT) is a treatment approach which can do both, through the local light activation of photosensitizers. However, current photosensitizers lack cancer specificity, which limits therapeutic efficacy and prolongs photosensitivity in patients. Recently, Dr. Oliveira has developed an improved version of targeted PDT that uses small antibody fragments, i.e. nanobodies, to target the photosensitizer to cancer cells. Nanobodies distribute homogenously, bind rapidly and specifically to cancer cells, and are quickly eliminated when unbound. Within the ERC StG KILLCANCER project, the team has been focusing on better understanding the mechanism of nanobody-targeted PDT, its potential to induce tumor regression in vivo, and its capacity to trigger the immune system for long term protection. Results indicate this treatment could lead to improved selectivity and reduced side effects, compared to conventional PDT and antibody-targeted PDT. The fundamental objective of this ERC PoC is to ascertain the technical and commercial viability of nanobody-targeted PDT for treatment of head and neck cancer. Within this project, the aims are to: 1. Humanize the lead nanobody, validate the results, and explore GMP production 2. Perform an IP landscape analysis and establish freedom-to-operate (FTO) 3. Execute an extensive market, competitor, and stakeholder analysis, and 4. Develop a detailed business plan based on this information to accurately guide commercialisation. Together, these steps will be essential for nanobody-targeted PDT to be ready for the translation to humans, so that cancer patients and society as a whole can benefit from this promising alternative treatment.

Original sub-sector

Obfuscated

Original Currency

USD

Original budget

000000000000000

Procurement method

Obfuscated Data

Budget

000000000000000

Location

Region

Obfuscated

Country

Obfuscated

State

Obfuscated Data

County

Obfuscated

Location

Obfuscated Data, Obfuscated data, obfuscated data, Obfuscated data

Source

Source reliability

High

Data quality score

100%

Source

Obfuscated Data

URL

obfuscated_data,obfuscateddata.com

More Details

Project Type

Obfuscated Data

Article Published Date

Obfuscated Data